Saturday, December 2, 2023
WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.
President
European Atherosclerosis Society
Professor of Public Health and Honorary Consultant Cardiologist
Director
Imperial Centre for Cardiovascular Disease Prevention
Deputy Director
Imperial Clinical Trials Unit
Head of Commercial Trials
Imperial College London
London, United Kingdom
President
International Lipid Expert Panel (ILEP)
President
Polish Lipid Association (PoLA)
Head and Professor
Department of Preventive Cardiology and Lipidology
Medical University of Lodz (MUL)
Lodz, Poland;
Head
Cardiovascular Research Center
University of Zielona Góra
Zielona Góra, Poland
Director of Research (Professor) in Translational Therapeutics
Executive Director
Centre for Naturally Randomised Trials
University of Cambridge
Cambridge, United Kingdom
Professor
Chief Physician
Copenhagen University Hospital and Faculty of Health and Medical Sciences
University of Copenhagen
Copenhagen, Denmark
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
This educational activity is intended for an international audience of non-US cardiologists, primary care physicians, and diabetologists/endocrinologists.
The goal of this activity is that the learner will be better able to appropriately use lipid-lowering therapy in patients at high and very-high cardiovascular risk to achieve LDL-C goals and maintain adherence for the long term.
Upon completion of this activity, participants will:
WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.
President
European Atherosclerosis Society
Professor of Public Health and Honorary Consultant Cardiologist
Director
Imperial Centre for Cardiovascular Disease Prevention
Deputy Director
Imperial Clinical Trials Unit
Head of Commercial Trials
Imperial College London
London, United Kingdom
President
International Lipid Expert Panel (ILEP)
President
Polish Lipid Association (PoLA)
Head and Professor
Department of Preventive Cardiology and Lipidology
Medical University of Lodz (MUL)
Lodz, Poland;
Head
Cardiovascular Research Center
University of Zielona Góra
Zielona Góra, Poland
Director of Research (Professor) in Translational Therapeutics
Executive Director
Centre for Naturally Randomised Trials
University of Cambridge
Cambridge, United Kingdom
Professor
Chief Physician
Copenhagen University Hospital and Faculty of Health and Medical Sciences
University of Copenhagen
Copenhagen, Denmark
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.75 continuing professional development credits (CPD).
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information about your
eligibility to claim credit, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must
complete the activity online during the credit eligibility period that is noted on the title page.
Follow these steps to claim a credit certificate for completing this activity:
We encourage you to complete an Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
CPD Released: 9/20/2022
Valid for credit through: 9/20/2023, 11:59 PM EST
processing....
All sections of this activity are required for credit.
The goal of this activity is that the learner will be better able to appropriately use lipid-lowering therapy in patients at high and very-high cardiovascular risk to achieve LDL-C goals and maintain adherence for the long-term.
Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.
